Comment
doi: 10.1016/S2215-0366(23)00141-4.
The use of long-acting injectables in early-phase schizophrenia
Affiliations
- PMID: 37353254
- DOI: 10.1016/S2215-0366(23)00141-4
Item in Clipboard
Comment
The use of long-acting injectables in early-phase schizophrenia
Lancet Psychiatry.
2023 Jul.
No abstract available
Conflict of interest statement
MZP declares no competing interests. RLP has received speaker honoraria from Abbvie, Alkermes, Idorsia, Intracellular, Janssen, Jazz, Lumbeck, Neuronetics, Otsuka, and Supernus.
Comment in
-
The use of long-acting injectables in early-phase schizophrenia - Authors' reply.Lancet Psychiatry. 2023 Jul;10(7):482-483. doi: 10.1016/S2215-0366(23)00182-7. Lancet Psychiatry. 2023. PMID: 37353257 No abstract available.
Comment on
-
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).Lancet Psychiatry. 2023 Mar;10(3):197-208. doi: 10.1016/S2215-0366(23)00005-6. Epub 2023 Jan 27. Lancet Psychiatry. 2023. PMID: 36716759 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
